Astrid Borkowski Sells 10,000 Shares of HilleVax, Inc. (NASDAQ:HLVX) Stock

HilleVax, Inc. (NASDAQ:HLVXGet Free Report) insider Astrid Borkowski sold 10,000 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now directly owns 195,193 shares in the company, valued at $2,732,702. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Astrid Borkowski also recently made the following trade(s):

  • On Wednesday, November 8th, Astrid Borkowski sold 5,000 shares of HilleVax stock. The stock was sold at an average price of $13.00, for a total value of $65,000.00.

HilleVax Stock Performance

Shares of NASDAQ:HLVX traded up $0.31 during midday trading on Monday, hitting $13.89. The company’s stock had a trading volume of 165,499 shares, compared to its average volume of 64,149. HilleVax, Inc. has a fifty-two week low of $9.94 and a fifty-two week high of $22.21. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.58 and a current ratio of 17.58. The stock has a market capitalization of $672.79 million, a price-to-earnings ratio of -4.87 and a beta of 0.11. The stock’s 50 day simple moving average is $12.61 and its 200 day simple moving average is $14.30.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HLVX. Guggenheim reduced their target price on HilleVax from $38.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, November 15th. Stifel Nicolaus reduced their price objective on shares of HilleVax from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, November 10th.

View Our Latest Research Report on HLVX

Institutional Trading of HilleVax

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acuta Capital Partners LLC lifted its holdings in shares of HilleVax by 328.5% during the third quarter. Acuta Capital Partners LLC now owns 270,319 shares of the company’s stock worth $3,636,000 after buying an additional 207,241 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in HilleVax during the 3rd quarter valued at $2,374,000. 683 Capital Management LLC bought a new stake in HilleVax in the 3rd quarter valued at $1,630,000. Braidwell LP grew its position in HilleVax by 16.0% in the 3rd quarter. Braidwell LP now owns 1,449,246 shares of the company’s stock worth $19,492,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Seven Grand Managers LLC bought a new position in shares of HilleVax during the 3rd quarter worth about $200,000. Institutional investors and hedge funds own 89.77% of the company’s stock.

About HilleVax

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

Read More

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.